Middle East & Africa Insulin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

List of Tables

The insulin market in MEA is expected to grow from US$ 3,255.91 million in 2022 to US$ 5,549.57 million by 2028. It is estimated to grow at a CAGR of 9.2% from 2022 to 2028.

Insufficient Competition from Biosimilars to Provide Opportunities in Market

The dominance of major players in the Middle East & Africa has led to an increase in the insulin market value. Novo Nordisk A/S, Elli Lily and Company, and Sanofi have a cumulative market revenue of over 90%. This is majorly credited to the evergreening of patents currently held by these dominating players. Moreover, patients' lack of trust in biosimilar drugs is a significant factor augmenting the insulin market growth. According to a study conducted by Health Action International (2019), states that Eli Lilly and Company, Novo Nordisk, and Sanofi are the only three manufacturers of insulin, and they generate ~90% of revenue in the market.

Market Overview

The insulin market in the Middle East & Africa is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The region is expected to present notable growth opportunities to market players owing to the rise in the prevalence of diabetes, surge in healthcare expenditure, increasing awareness about diabetes, and preventive measures being taken to control the incidences of diabetes. In Saudi Arabia, diabetes affects ~20% of the population. The disease accounts for one-fourth of the total healthcare expenditure in the country. Diabetes mellitus is the prevalent form of diabetes in the country. According to International Diabetes Federation, in 2019, ~7 million people in Saudi Arabia had diabetes. The country ranks eighth in terms of the prevalence of diabetes, including children and adults living with type 1 diabetes mellitus. It is the 4th country in the world in terms of the incidence rate, as ~33.5 per 1 million people are affected by type 1 diabetes mellitus.

MEA Insulin Market Revenue and Forecast to 2028 (US$ Million)

MEA Insulin Market Segmentation

The MEA insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.

Based on long acting insulin, the MEA insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.

Based on short acting insulin and traditional human insulin, the MEA insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.

Based on concentrated insulin and combination insulin, the MEA insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.

Based on biosimilar insulin, the MEA insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022.

Based on country, the market is segmented into Saudi Arabia, South Africa, UAE, and Rest of MEA. Saudi Arabia dominated the market share in 2022.

Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA insulin market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA insulin market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00027244

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 MEA Insulin Market - By Type
- 1.3.2 MEA Insulin Market - By Country

2. MEA Insulin Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. MEA Insulin Market - Market Landscape

4.1 Overview
4.2 MEA PEST Analysis
- 4.2.1 Expert Opinion

5. MEA Insulin Market- Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Incidence of Diabetes
- 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
- 5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
- 5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
- 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis

6. Insulin Market- MEA Analysis

6.1 MEA Insulin Market Revenue Forecast and Analysis

7. MEA Insulin Market Analysis - By Type

7.1 Overview
7.2 MEA Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
- 7.3.1 Overview
- 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.1 Levemir
    - 7.3.2.1.1 Overview
    - 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.2 Lantus
    - 7.3.2.2.1 Overview
    - 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.3 Basaglar
    - 7.3.2.3.1 Overview
    - 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.4 Tresiba
    - 7.3.2.4.1 Overview
    - 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
- 7.4.1 Overview
- 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 Novolog
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.2 Humalog
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.3 Admelog
    - 7.4.2.3.1 Overview
    - 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.4 Others
    - 7.4.2.4.1 Overview
    - 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
- 7.5.1 Overview
- 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 Novolin R
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.2 Humulin R
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.3 Insuman
    - 7.5.2.3.1 Overview
    - 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.4 Others
    - 7.5.2.4.1 Overview
    - 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
- 7.6.1 Overview
- 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 NovoMix
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.2 Ryzodeg
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.3 Xultophy
    - 7.6.2.3.1 Overview
    - 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.4 Soliqua/Suliqua
    - 7.6.2.4.1 Overview
    - 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
- 7.7.1 Overview
- 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.1 Insulin Glargine
    - 7.7.2.1.1 Overview
    - 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.2 Human Insulin
    - 7.7.2.2.1 Overview
    - 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
- 7.8.1 Overview
- 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
- 7.9.1 Overview
- 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)

8. MEA Insulin Market - Country Analysis

8.1 Overview
- 8.1.1 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
  - 8.1.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.1.2 UAE: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.1.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.1.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.1.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.1.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.2.2 Saudi Arabia: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.1.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.1.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.1.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.1.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.3.2 South Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.1.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.1.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.1.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.1.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.1.1.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.1.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.1.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.1.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.1.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)

9. MEA Insulin Market-Industry Landscape

9.1 Overview
9.2 Organic Developments
- 9.2.1 Overview
9.3 Inorganic Developments
- 9.3.1 Overview

10. Company Profile

10.1 Eli Lilly and Company
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 Novo Nordisk A/S
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Biocon
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Wockhardt
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 GlaxoSmithKline plc.
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Sanofi
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Pfizer Inc.
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Merck & Co., Inc.
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments

11. Appendix

11.1 About The Insight Partners
11.2 Glossary of Terms